Deakin University
Browse

File(s) not publicly available

Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children

Version 2 2024-06-13, 15:26
Version 1 2022-03-31, 12:22
journal contribution
posted on 2004-12-15, 00:00 authored by R B Belshe, F K Newman, E L Anderson, P F Wright, R A Karron, S Tollefson, F W Henderson, H C Meissner, S Madhi, D Roberton, H Marshall, R Loh, Peter Sly, B Murphy, J M Tatem, V Randolph, J Hackell, W Gruber, T F Tsai
We evaluated a combination respiratory syncytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated intranasal vaccine for safety, viral replication, and immunogenicity in doubly seronegative children 6-18 months old. RSV cpts-248/404 and PIV3-cp45 vaccines were combined in a dose of 10 5 plaque-forming units of each per 0.5-mL dose and compared with monovalent vaccines or placebo. The virus shedding pattern of RSV was not different between monovalent RSV cpts-248/404 vaccine and combination vaccine. Modest reductions in the shedding of PIV3-cp45 vaccine virus were found after the administration of RSV cpts-248/404 and PIV3-cp45 vaccine, relative to monovalent PIV3 vaccine; 16 (76%) of 21 children given combination vaccine shed PIV3-cp45 versus 11 (92%) of 12 of those given monovalent PIV3 vaccine. Both vaccines were immunogenic, and antibody responses were similar between the monovalent groups and the combination group. Combined RSV/ PV3 vaccine is feasible for simultaneous administration, and further studies are warranted.

History

Journal

Journal of Infectious Diseases

Volume

190

Issue

12

Pagination

2096 - 2103

ISSN

0022-1899

Usage metrics

    Research Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC